Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies.

Phan LM, Yeung SC, Lee MH. · 2014

Read Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. by Phan LM, Yeung SC, Lee MH. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3969803.txt.

Introduction

Liem Minh Phan, Sai-Ching Jim Yeung, and Mong-Hong Lee review how cancers rewire their metabolism in Cancer Biology and Medicine in 2014. Since Otto Warburg's 1930s discovery that tumor cells ferment sugar even when oxygen is plentiful, altered metabolism has become a recognized hallmark of cancer. Rewired energy systems feed rapid growth, survival in harsh conditions, invasion, spread, and resistance to treatment.

The review covers the main features: heavy glucose fermentation, glutamine burning, and stepped-up building of mitochondria, all tied to the cell cycle machinery. It then surveys recent advances and asks which of these metabolic quirks can be turned into precise drug targets or diagnostic tests. The authors frame metabolism as a vulnerability that runs across many tumor types rather than a side effect of growth.

Catalog record

CREATORPhan LM, Yeung SC, Lee MH.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE86 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3969803

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies By Liem Minh Phan, Sai-Ching Jim Yeung, Mong-Hong Lee Published in: Cancer Biology & Medicine DOI: 10.7497/j.issn.2095-3941.2014.01.001 ABSTRACT Abstract Cancer cells are well documented to rewire their metabolism and energy production networks to support and enable rapid proliferation, continuous growth, survival in harsh conditions, invasion, metastasis, and resistance to cancer treatments. Since Dr. Otto Warburg’s discovery about altered cancer cell metabolism in 1930, thousands of studies have shed light on various aspects of cancer metabolism with a common goal to find new ways for effectively eliminating tumor cells by targeting their energy metabolism. This review highlights the importance of the main features of cancer metabolism, summarizes recent remarkable advances in this field, and points out the potentials to translate these scientific findings into life-saving diagnosis and therapies to help cancer patients. KEYWORDS : Cell cycle, energy metabolism, glycolysis, glutaminolysis, mitochondria biogenesis CANCER METABOLISM: MAJOR REMODELING OF CELLULAR ENERGY PRODUCTION AND METABOLIC PATHWAYS IN TUMORS Cancer metabolic reprogramming has been recognized as one of the ten cancer hallmarks by Drs. Hanahan and Weinberg in their seminal review paper published in 20111. Some of the most striking changes of tumor cellular bioenergetics include elevation of glycolysis, increase in glutaminolytic flux, upregulation of amino acid and lipid metabolism, enhancement of mitochondrial biogenesis, induction of pentose phosphate pathway and macromolecule biosynthesis1-17. Glycolysis Compared to normal cells, cancer cells prefer using glycolysis even in normoxic condition18-20. This phenomenon is often referred as the Warburg effect because Dr. Otto Warburg discovered and reported these metabolic alterations in tumors in 1930 and 195618-20. Many decades later, numerous studies have provided additional insights into the abnormality of cancer metabolism. In normal cells, glucose is catabolized to pyruvate, which can be later converted to acetyl-CoA to fuel the tricarboxylic acid cycle (TCA cycle, or Krebs cycle). TCA cycle generates NADH and FADH2 to provide mitochondrial respiratory chain with electrons for energy production. This is an effective energy production mode since each glucose molecule can produce up to 36 ATP, largely thanks to mitochondrial respiration. In normal cells, glycolysis is prioritized only when oxygen supply is limited. In contrast, cancer cells preferentially use glycolysis even in the abundance of oxygen2,3,5,7,18-21. This is why tumor glycolysis is often called “aerobic glycolysis”, or the Warburg effect, to distinguish from the normal anaerobic glycolysis of healthy cells. However, cancer cells have to compensate for the 18-fold lower efficacy of energy generation (glycolysis only makes 2 ATP per glucose molecule consumed while mitochondrial respiration can produce up to 36 ATP for each glucose molecule catabolized). Part of the solution is to upregulate glucose transporters, especially Glut1, Glut2, Glut3, and Glut4, to uptake more glucose5,22-24. In fact, the increase in glucose uptake is a major feature distinguishing tumor cells from normal cells. This difference has been widely exploited in Positron Emission Tomography (PET) imaging modality using radiolabeled analogs of glucose such as 18F-fluorodeoxyglucose as a tracer to visualize tumors. In addition, tumors remarkably elevate the expression of the majority of glycolytic enzymes. Major oncogenes such as Ras, Myc, and HIF-1α are reported to be master inducers of cancer glycolysis3,5,24. Many glycolytic enzymes are also upregulated in tumors because of elevated c-Myc and HIF-1α transcriptional activity and insufficient p53-mediated control. Indeed, c-Myc and HIF-1α are well recognized as two master inducers of glycolysis through direct or indirect transactivation of cancer glycolytic genes. These two transcription factors coordinate to promote the expression of key glycolytic enzymes such as HK2, PFK1, TPI1, LDHA, among others, in tumors2,3,5,7,21,25,26. In fact, most of glycolytic gene promoter areas contain consensus Myc and HIF-1α binding motifs. While HIF-1α is mainly functional in hypoxia, c-Myc is well known to promote its glycolytic target genes’ expression in normoxia. This coordination allows tumors to continuously drive glycolysis for supporting their rapid proliferation and accelerated biosynthesis2,3,7,11,15,16,21. In contrast, p53 is known to suppress glucose uptake by directly inhibiting the transcription of glucose transporter Glut1 and Glut427,28 and suppressing the expression of Glut328. Glut3 is an NF-κB target gene and p53 is found to block NF-κB activation, thereby considerably reducing Glut3 transcription and expression28. p53 also induces the expression of TIGAR to slow down cancer glycolytic flux29,30. Fructose 2,6-bisphosphate is an important allosteric activator of PFK1, a major glycolytic enzyme. Fructose 2,6-bisphosphate is produced by PFK2 from fructose 1-phosphate. By converting fructose 2,6-bisphosphate back to fructose 1-phosphate, TIGAR significantly slows down tumor glycolysis29,30. The interaction among p53, c-Myc and HIF-1α has a decisive impact on the status of cancer glycolysis2,5,7,16,21,30. Many studies have characterized the communication between these three master regulators of cancer glycolysis and how the balance among these factors control the status of cancer metabolism. On the other hand, the way tumor cells process pyruvate, the end product of glycolysis, is also different from normal cells. In normal cells, most of pyruvate is converted to acetyl-CoA to fuel the TCA cycle. Some pyruvate is used to produce alanine or lactate. In contrast, pyruvate-to-lactate is a preferred reaction in tumor cells due to the upregulation of lactate dehydrogenase A (LDHA). This reaction is beneficial for cancer cells as it helps regenerate NADH to accelerate glycolysis2,3,5,11,25. Furthermore, lactate is secreted into tumor microenvironment via MCT4 transporter to fuel other cancer cells that do not have frequent access to nutrient supplies from blood stream. Lactate could be uptaken by MCT1 transporter and used by the TCA cycle for metabolism. The symbiosis of lactate-producing cancer cells and lactate-consuming tumor cells is an effective way for tumors’ adaptation to the diverse and constantly changing conditions in tumors, which is caused by the leaky and poorly formed tumor blood vessel network7,31-33. Furthermore, converting pyruvate to lactate also reduces reactive oxygen species’ levels, thereby diminishing the intracellular oxidative stress in cancer cells and promoting tumors’ survival2,7. Moreover, lactate also lowers the pH of extracellular microenvironment and facilitates the activity of metalloproteases for breaking down extracellular matrix. Thus, lactate is an inducer of cancer invasion and metastasis34,35. Importantly, glycolysis provides cancer cells with not only energy but also necessary precursors for biosynthesis, which is similar to stem cells’ metabolic profiles. Several glycolytic metabolites such as glucose-6-phosphate, dihydroxyacetone phosphate, among others, could be diverted into other metabolic pathways. For instance, glucose-6-phosphate is often consumed by pentose phosphate pathway to synthesize nucleotides and NADPH (a major reducing agent important for redox homeostasis and drug detoxifying reactions). Dihydroxyacetone phosphate could be used for lipid synthesis, which is important for assembling new organelles and cells to promote tumor growth and proliferation. Metabolites from glycolysis are also important materials for amino acid production and macromolecules synthesis, which is required for active cell division and large-scale biosynthetic programs2,3,5,7,16,36,37. In addition to their metabolic function, glycolytic enzymes play active roles in promoting cancer survival, metastasis, invasion, chromatin remodeling, gene expression regulation, and other essential cellular processes2,38. Thus targeting glycolytic enzymes’ activities could be useful strategies for cancer therapy. Glutaminolysis In addition to glycolysis, many tumors also rely on glutaminolysis to fuel their cellular bioenergetics and metabolism. Glutaminolysis is a series of biochemical reactions catabolizing glutamine into downstream metabolites such as glutamate, α-ketoglutarate. The products of glutaminolysis are very important to fuel the TCA cycle of tumors. The

Read the complete text